EASD 2019 — Degludec reduces fasting plasma glucose, may lower risk of severe hypoglycemic events


  • Brandon May
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Treatment with degludec may result in greater glycemic control and a lower risk of severe hypoglycemic events vs glargine in patients with type 2 diabetes (T2D).

Why this matters

  • Patients with T2D are at risk of poorly controlled disease and hypoglycemic events.

Study design

  • Patients with T2D were randomly assigned:
    • Once-daily degludec U200 with or without oral antidiabetic drugs (n=805);
    • Once-daily glargine U300 with or without oral antidiabetic drugs (n=804).
  • The primary endpoint included the number of severe or blood glucose-confirmed symptomatic hypoglycemic events during the 36-week maintenance period.
  • Funding: Novo Nordisk.

Key results

  • No difference was observed between the degludec and glargine groups for the primary endpoint (risk ratio [RR], 0.88; 95% CI, 0.73-1.06; P=.17).
  • The risk of nocturnal symptomatic events was lower in the degludec arm vs the glargine group (RR, 0.63; 95% CI, 0.48-0.84; P=.0014).
  • Treatment with degludec was associated with fewer severe hypoglycemic events requiring third-party assistance (RR, 0.20; 95% CI, 0.07-0.57; P=.0027).
  • Fasting plasma glucose was lower in the degludec arm at 88 weeks (5.9 vs 6.5 mmol/L; estimated treatment difference, −0.62 mmol/L; 95% CI, −0.82 to −0.43; P<.0001>

Limitations

  • Relatively short follow-up period.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit